An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain

Phase 2

Terminated

• Conditions: Herpes Zoster; Neuralgia; Pain; HIV Infections; Peripheral Nervous System Diseases; Diabetic Neuropathies; Diabetes Mellitus; Polyneuropathies

• Registration Number: NCT00089557
• Lead Sponsor: NeurogesX

Brief Summary

This study is an open-label, multicenter, extension study for subjects who completed NeurogesX Study C111 and received treatment with NGX-4010 (Capsaicin Patch) within 12 weeks (up to +7days) before entry into Study C114

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2004-08-06
• Study First Submitted QC: 2004-08-06
• Study First Posted: 2004-08-09
• Status Verified: 2004-09
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified